ICICI Securities has assigned a 'BUY' rating to HealthCare Global Enterprises (HCG) with a target of Rs 800. The brokerage highlights the company’s recent revenue growth and future capacity expansion plans, though investors should also note risks regarding rising operational costs and margin performance.
ICICI Securities has initiated coverage on HealthCare Global Enterprises (HCG), assigning a 'BUY' rating and setting a price target of Rs 800 per share. The brokerage's positive outlook is largely tied to the company's long-term expansion plans and potential for operational efficiency, though it notes specific challenges in the current financial environment.
In the first quarter of fiscal year 2027, the company reported consolidated revenue of approximately Rs 693 to 695 crore, reflecting a year-on-year growth of about 13%. While this growth is notable, it fell slightly short of the company's internal guidance of 15% or higher. On the bottom line, HCG posted a significant jump in net profit, which rose by roughly 190% year-on-year to Rs 13.77 crore. Performance was supported by strong demand in the company's South and East region hospitals, which helped offset a slower performance in western markets.
Looking ahead, HCG has set an ambitious goal to reach 3,670 beds by the end of the 2030 fiscal year, a significant increase from the 2,734 beds recorded in FY26. This expansion strategy includes both new facility builds and adding capacity to existing hospitals. To streamline its business and improve focus, the company has completed its exit from the Milann fertility business, a move aimed at enhancing overall profitability by concentrating resources on its core oncology and multi-specialty hospital business.
Despite these growth plans, investors should be aware of several operational risks. Profit margins have faced pressure, with EBITDA margins currently hovering in the 17.6% to 19.4% range. This has raised concerns about the company's ability to achieve consistent annual margin improvement. Furthermore, operating expenses, particularly medical consultancy charges, have grown at a faster pace than revenue in recent quarters, which can squeeze the company’s ability to generate cash.
The healthcare sector is also experiencing intense competition, with potential regulatory risks such as government-imposed caps on hospital room rates adding uncertainty. Additionally, the heavy capital expenditure required for the planned expansion could affect the company’s short-term debt levels and cash flow. For shareholders, the most important monitorable over the coming quarters will be how effectively management executes its capacity expansion plans while controlling rising operational costs to ensure that margins move toward the targeted 21-25% range.